Epidermal growth factor receptor: mechanisms of activation and signalling.

By Robert N. Jorissen, F. Walker, N. Pouliot, Thomas P. J. Garrett, Colin W. Ward, Antony W. Burgess. Experimental Cell Research, 2003

1,514 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/276d8bf6fb63c42eeaa9f9cb428c2f5a7e339778

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. N. Hynes
2. C. Blobel
3. M. Lemmon
4. Gwen Macdonald
5. D. Leahy
6. Thomas Holbro
7. P. Johnston
8. Hyun-soo Cho

In Oncology

1. N. Hynes
2. C. Blobel
3. Gwen Macdonald
4. P. Jänne
5. D. Leahy
6. Thomas Holbro
7. P. Johnston
8. M. Sliwkowski

In Radiology, Nuclear Medicine and Imaging

1. N. Hynes
2. C. Blobel
3. Gwen Macdonald
4. Thomas Holbro
5. P. Johnston
6. M. Sliwkowski
7. D. Longley
8. J. Baselga

Citations in the corpus

• Oncogenic Transformation by Inhibitor-Sensitive and -Resistant EGFR Mutants (2005, background): “Stimulation of the receptor with EGF or other cognate ligands induces receptor dimerization and autophosphorylation, providing docking sites for SH2containing adaptor proteins that mediate the activation of intracellular signaling pathways [1–3].”
• ADAMs: key components in EGFR signalling and development (2005, background): “The crystal structures of the soluble EGFR ectodomain with or without a bound soluble ligand (TGFα or EGF) have been solve”
• ErbB receptors and signaling pathways in cancer. (2009, background): “Genetic changes that have been detected in human tumors include gene amplification leading to receptor overexpression, activating kinase domain mutations mainly in EGFR, but also in ErbB2 [6–8], in-frame deletions in the extracellular domain of EGFR (EGFR vIII) [9], and coexpression of ErbB ligands ”
• Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. (2004, background): “state, the domain II hairpin now protrudes out from the rest of (Jorissen et al., 2003), and the consequent recruitment of various”
• ErbB receptors: directing key signaling networks throughout life. (2004, background): “Other cytoplasmic docking proteins appear to be recruited by specific ErbB receptors and less exploited by others (35).”
• An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. (2003, background): “…40 years ago (Cohen, P.O. Box 2008 1960), epidermal growth factor (EGF) has provided nuRoyal Melbourne Hospital merous puzzles for biologists, biochemists, physicists, 3 Walter and Eliza Hall Institute of Medical Research and oncologists (Jorissen et al., 2003; Schlessinger, 1G Royal Parade 2002).”
• Quantum dot ligands provide new insights into erbB/HER receptor–mediated signal transduction (2004, background): “Activation of these transmembrane proteins initiates signaling cascades controlling numerous cellular processes such as DNA replication and divisio”
• Molecular mechanisms of drug resistance (2005, background): “Antiapoptotic downstream signals activated by these receptor tyrosine kinases include the phosphatidylinositol 3-kinase (PI3K)/Akt (protein kinase B, PKB) pathway and the STAT (signal transducers and activators of transcription) pathway, specifically STAT3 and STAT5 (see below) [206,207].”